News|Articles|May 9, 2023

PI Healthsciences Acquires Archimica S.p.A from Livia Group

Author(s)Jill Murphy

The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.

PI Healthsciences acquired Archimica S.p.A, an API manufacturer located in Lodi, Italy, on April 28, 2023, with the intention to provide Archimica the opportunity to integrate their value chain and enhance the security of supplies by using PI’s technological excellence, according to the press release.

PI Healthscienes, a specialty chemical company in India, has more than 3500 employees, three formulation facilities, and 15 multi-product plants. The company’s facilities integrate process development with in-house engineering. It’s R&D facility in Udaipur has a dedicated team of more than 500 scientists and chemists. The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.

“We are excited about this acquisition as it marks a solid and accelerated beginning of PI’s journey in the pharma space. Our unique ability to build concrete offerings from abstract situations and leverage our capabilities across complex chemistries in the value chain will once again help create a differentiated value proposition for our stakeholders,” said Mayank Singhal, Vice Chairperson & Managing Director of PI Industries Ltd., in a press release. “This acquisition aligns with PI’s approach of working with global innovators and being at the forefront of innovation, science, technology and human ingenuity to create transformative solutions in life sciences with the purpose of reimagining a healthier planet. We are excited to welcome the talented team from Archimica to the PI family. We look forward to deploying all our combined expertise towards unique value delivery for our customers. I compliment PI’s leadership team and external advisors in fructifying this strategic opportunity.”

Source: Archimica


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.